What is the 13F Pro Quality Score for SBFM?

13F Pro ranks Sunshine Biopharma Inc. (SBFM) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SBFM's current score at https://13fpro.ai/company/SBFM (free sign-up required for the full ranking).

Which hedge funds own the most SBFM stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of SBFM include JANE STREET GROUP,, MORGAN STANLEY, UBS Group AG. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/SBFM as soon as new 13F filings post.

Where does 13F Pro source SBFM data?

All Sunshine Biopharma Inc. fundamentals and ownership data come directly from SEC EDGAR. Sunshine Biopharma Inc. files with the SEC under CIK 1402328. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SBFM in?

Sunshine Biopharma Inc. (SBFM) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is SBFM research updated on 13F Pro?

SBFM's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Sunshine Biopharma Inc.(SBFM)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1402328 SBFM stock profile & AI dashboard →

13F Pro Quality Score

33.1/100

Rank #2,247 of 2,819 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

85.8/100

Profitability

17.0/100

Balance Sheet

11.9/100

Earnings Quality

16.3/100

Free Cash Flow

14.4/100

Institutional Flow

19.9/100

Revenue Scale

8.0/100

Dilution Risk

94.6/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why SBFM Scores 33/100

exact factor attribution · 2026-08-16

SBFM's composite is driven by revenue growth and shareholder dilution, held back by scale and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+7.2 pts

86th pct

Shareholder dilution

+2.2 pts

95th pct

Earnings growth

-1.0 pts

30th pct

Institutional flow

-1.5 pts

20th pct

Earnings quality

-3.4 pts

16th pct

Capital efficiency

-3.8 pts

12th pct

Profitability

-5.0 pts

17th pct

Free cash flow

-5.3 pts

14th pct

Scale

-6.3 pts

8th pct

Latest change (2026-08-16): 34 → 29 · ↓ Revenue growth 94→65

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

SBFM Stock Analysis & AI Quality Score

Data updated 2026-08-16

AI stock analysis and institutional research for Sunshine Biopharma Inc. (SBFM), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SBFM at 33.1/100 on a 32-signal composite quality model, placing it at rank #2,247 of 2,819 stocks — the bottom half of the AI-ranked universe. SBFM scores in the top quartile across revenue growth (85.8). Areas of concern include revenue scale (8.0) and balance sheet strength (11.9), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), Sunshine Biopharma Inc. reports quarterly revenue of $9.3M, net income of $-1.6M, an operating margin of -17.4%. Top institutional holders of SBFM by reported 13-F value include JANE STREET GROUP, MORGAN STANLEY, UBS Group AG, based on the most recent SEC filings. SBFM trades on the Nasdaq exchange and files with the SEC under CIK 1402328. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SBFM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Sunshine Biopharma Inc. directly from SEC EDGAR. Sunshine Biopharma Inc.'s 13F Pro composite quality score has ranged between 29 and 33 since 2026, currently 33.1 — an improving long-term trajectory across 30 quarterly and live scoring snapshots.

Revenue

Q2 2026

$9.3M

Net Income

Q2 2026

$-1.6M

Free Cash Flow

Q2 2026

$-925.0K

Operating Margin

Q2 2026

-17.4%

ROIC

Q2 2026

-23.4%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+4.1% YoY

$36.3MFY 2025

FY22 $4.3MFY23 $24.1MFY24 $34.9MFY25 $36.3M

Net Income

-16.4% YoY

$-6.0MFY 2025

FY22 $-26.7MFY23 $-4.5MFY24 $-5.1MFY25 $-6.0M

Operating Income

-7.1% YoY

$-6.2MFY 2025

FY22 $-27.0MFY23 $-4.8MFY24 $-5.8MFY25 $-6.2M

EPS (Diluted)

—FY 2025

FY22 $-0.25FY23 $-49.49FY24 $-7.32FY25 —

Total Assets

-1.6% YoY

$30.1MFY 2025

FY22 $29.2MFY23 $27.3MFY24 $30.6MFY25 $30.1M

Total Debt

—FY 2025

FY22 —FY23 —FY24 —FY25 —

Op. Cash Flow

+57.4% YoY

$-5.3MFY 2025

FY22 $-5.2MFY23 $-8.8MFY24 $-12.5MFY25 $-5.3M

Free Cash Flow

+61.2% YoY

$-5.5MFY 2025

FY22 $-5.4MFY23 $-8.9MFY24 $-14.2MFY25 $-5.5M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$36.3M +4.1%	$34.9M +44.7%	$24.1M +454.4%	$4.3M +1802.4%	$228.4K +219.9%	$71.4K
Net Income	$-6.0M -16.4%	$-5.1M -13.9%	$-4.5M +83.2%	$-26.7M -115.0%	$-12.4M -346.7%	$-2.8M
Operating Income	$-6.2M -7.1%	$-5.8M -21.5%	$-4.8M +82.3%	$-27.0M -1006.5%	$-2.4M -323.0%	$-576.9K
EPS (Diluted)	—	$-7.32 +85.2%	$-49.49 -19862.6%	$-0.25 +63.0%	$-0.67	—
Total Assets	$30.1M -1.6%	$30.6M +11.8%	$27.3M -6.5%	$29.2M +1227.5%	$2.2M +110.7%	$1.0M
Total Debt	—	—	—	—	—	$949.0K
Operating Cash Flow	$-5.3M +57.4%	$-12.5M -42.7%	$-8.8M -67.2%	$-5.2M -186.9%	$-1.8M -178.3%	$-657.3K
Free Cash Flow	$-5.5M +61.2%	$-14.2M -60.1%	$-8.9M -62.7%	$-5.4M -197.5%	$-1.8M -177.8%	$-658.5K

Get alerted when SBFM's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Sunshine Biopharma Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SBFM

Fund	Value	Shares
JANE STREET GROUP, LLC	$31.4K	14,974
MORGAN STANLEY	$808.00	385
UBS Group AG	$546.00	11,879
SBI Securities Co., Ltd.	$340.00	162
Clear Street Group Inc.	$27.00	449
NATIONAL BANK OF CANADA /FI/	$10.00	5
OSAIC HOLDINGS, INC.	$4.00	2
Farther Finance Advisors, LLC	$2.00	1
TD Waterhouse Canada Inc.	$2.00	1
Strive Financial Group ,LLC	$2.00	1

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SBFM on your watchlist

Track score changes the day Sunshine Biopharma Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SBFM a good stock to buy?

13F Pro's AI-powered analysis of Sunshine Biopharma Inc. (SBFM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SBFM are available on the SBFM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. SBFM is classified as a small company.

Which hedge funds own SBFM?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SBFM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Sunshine Biopharma Inc.'s investment landscape.